Abstracts tagged "Ankylosing spondylitis (AS)"

Abstract Number: 1001 • 2017 ACR/ARHP Annual Meeting
Persistence, Discontinuation, and Switching Patterns Among Ankylosing Spondylitis Patients Newly Initiating Biologic Therapy
Theresa Hunter¹, Krista Schroeder², Sarah Al Sawah² and David Sandoval Calderon², ¹Global Patient Outcomes and Real World Evidence, Eli Lilly and Company, Indianapolis, IN, ²Eli Lilly and Company, Indianapolis, IN
Background/Purpose: The primary goals of treating Ankylosing Spondylitis (AS) patients are to maximize long-term health-related quality of life through control of symptoms and inflammation, prevention…
Abstract Number: 1539 • 2017 ACR/ARHP Annual Meeting
High Retention Rate and Sustained Responses with Secukinumab 150mg in Patients with Active Ankylosing Spondylitis: 3-Year Results from a Phase 3 Study
Alan J. Kivitz¹, Helena Marzo-Ortega², Clarence Legerton³, Joachim Sieper⁴, Ricardo Blanco⁵, Martin Cohen⁶, Evie Maria Delicha⁷, Susanne Rohrer⁷ and Hanno Richards⁷, ¹Altoona Center for Clinical Research, Duncansville, PA, ²NIHR LBRC, LTHT and LIRMM, UoL, Leeds, United Kingdom, ³Low Country Rheumatology, Articularis Healthcare, Charleston, SC, ⁴University Clinic Benjamin Franklin, Berlin, Germany, ⁵Hospital Universitario Marqués de Valdecilla, Santander, Spain, ⁶McGill University, Montreal, QC, Canada, ⁷Novartis Pharma AG, Basel, Switzerland
Background/Purpose: Secukinumab provided sustained improvement in the signs and symptoms of ankylosing spondylitis (AS) over 2 years in the MEASURE 2 study (NCT01649375).1,2 Here we…
Abstract Number: 2496 • 2017 ACR/ARHP Annual Meeting
The Disease Course in Daily Clinical Practice in Radiographic and Non-Radiographic Axial Spondyloarthritis Patients; One-Year Follow-up Results of National-Subgroup of a Worldwide Observational Cohort Study
Servet Akar¹, Ilhan Sezer², Yasemin Yumusakhuylu³, Ayşen Akinci⁴, Kemal Erol⁵, Kenan Akgun⁶, Hatice Bodur⁷, Sebnem Ataman⁸, Omer Kuru⁹, Meltem Melikoglu¹⁰, Murat Karkucak¹¹, Nazli Derya Bugdayci¹², Duygu Ersozlu Bakirli¹³, Murat Birtane¹⁴, Tuncay Duruoz¹⁵, Sukran Erten¹⁶, Ediz Dalkilic¹⁷, Gülay KINIKLI¹⁸, Cemal Bes¹⁹, Ahmet Omma²⁰ and Aylin Rezvani²¹, ¹Rheumatology, Izmir Katip Celebi University, School of Medicine, Rheumatology, Izmir, Turkey, ²Physical Medicine and Rehabilitation-Rheumatology, Antalya Training and Research Hospital, Antalya, Turkey, ³Department of Physical Medicine and Rehabilitation, Istanbul Medeniyet University, Goztepe Training and Research Hospital, Istanbul, Turkey, ⁴Hacettepe University Medical School Department of Physical Medicine and Rehabilitation, Ankara, Turkey, ⁵Department of Physical Medicine and Rehabilitation, Division of Rheumatology, Erciyes University Faculty of Medicine, Kayseri, Turkey, ⁶Department of Physical Medicine and Rehabilitation, Istanbul University, Cerrahpasa Faculty of Medicine, Istanbul, Turkey, ⁷Department of Physical Medicine and Rehabilitation, Ankara Numune Training and Research Hospital, Ankara, Turkey, ⁸Department of Physical Medicine and Rehabilitation, Division of Rheumatology, Ankara University Faculty of Medicine, Ankara, Turkey, ⁹Department of Physical Medicine and Rehabilitation, 19 Mayis University, Faculty of Medicine, Samsun, Turkey, ¹⁰Department of Physical Medicine and Rehabilitation, Division of Rheumatology, Ataturk University School of Medicine, Erzurum, Turkey, ¹¹Department of Physical Medicine and Rehabilitation, Karadeniz Technical University, Faculty of Medicine, Farabi Hospital, Trabzon, Turkey, ¹²Department of Physical Medicine and Rehabilitation, Istanbul Physical Therapy and Rehabilitation Training and Research Hospital, Istanbul, Turkey, ¹³Department of Rheumatology, Adana Numune Training and Research Hospital, Adana, Turkey, ¹⁴Department of Physical Medicine and Rehabilitation, Trakya University Faculty of Medicine, Edirne, Turkey, ¹⁵Department of Physical Medicine and Rehabilitation, Division of Rheumatology, Marmara University, Faculty of Medicine, Pendik Training and Research Hospital, Istanbul, Turkey, ¹⁶Rheumatology, Yildirim Beyazit University Faculty Of Medicine, Ankara, Turkey, ¹⁷Department of Internal Medicine, Division of Rheumatology, Uludag University, School of Medicine, Rheumatology, Bursa, Turkey, ¹⁸Department of Rheumatology, Ankara University, Faculty of Medicine, Department of Internal Medicine, Rheumatology, Ankara, Turkey, ¹⁹Rheumatology, Bakırköy Dr. Sadi Konuk Training and Research Hospital, İstanbul, Turkey, ²⁰Department of Internal Medicine, Division of Rheumatology, Ankara Numune Training and Research Hospital, Ankara, Turkey, ²¹Department of Physical Medicine and Rehabilitation, Bezmialem Vakif University, Faculty of Medicine, Istanbul, Turkey
Background/Purpose: The natural history of axial spondyloarthritis (axSpA) has not been clearly established yet. The aim of this study is to evaluate the natural course…
Abstract Number: 1234 • 2017 ACR/ARHP Annual Meeting
How Machine Learning Statistics Can Change the Game of Data Analysis in Rheumatology: The Example a Study with 170 Patients with Rheumatoid Arthritis (ra) or Axial Spondyloarthritis (axspa)
Frédéric Guyard¹, Laure Gossec², Didier Leroy³, Thomas Lafargue¹, Michel Seiler³, Charlotte Jacquemin⁴, Anna Molto⁵, Jeremie Sellam⁶, Violaine Foltz⁴, Frédérique Gandjbakhch⁴, Christophe Hudry⁷, Stéphane Mitrovic⁴, Bruno Fautrel⁴ and Herve Servy⁸, ¹IMT, Orange, Nice, France, ²UPMC, University Paris 06, Pitié-Salpétrière Hospital, Paris, France, ³Healthcare, Orange, Paris, France, ⁴UPMC University Paris 06, Pitié-Salpétrière Hospital, Paris, France, ⁵Hôpital Cochin, Department of Rheumatology, Paris Descartes University, Paris, France, ⁶Rheumatology, Saint-Antoine Hospital, Paris, France, ⁷AP-HP Hôpital Cochin, Paris, France, ⁸e-health services, Sanoia, Gemenos, France
Background/Purpose: A link between flares and physical activity would confirm the objective consequences of flares. In the ActConnect study of patients with RA or axSpA,…
Abstract Number: 1540 • 2017 ACR/ARHP Annual Meeting
Comparison of Radiologic Parameters of Ankylosing Spondylitis Treated with Anti-TNF-α Versus Non-Steroidal Anti-Inflammatory Drugs and Sulfasalazine
Seung Min Son, Orthopaedic surgery, Pusan National University Yangsan Hospital, Yangsan, Korea, Republic of (South)
Background/Purpose: There are many studies about impact of TNF-inhibitors on radiographic progression but little data are available on the relationship between treatment agents and sagittal…
Abstract Number: 2503 • 2017 ACR/ARHP Annual Meeting
Does Maastricht Ankylosing Spondylitis Enthesitis Scores Differ between Ankylosing Spondylitis, Psoriatic Arthritis and Rheumatoid Arthritis Patients?
Steffan Robstad Nilssen¹, Jintana B: Andersen¹, Hanne K. Vestaby¹, Glenn Haugeberg² and Brigitte Michelsen³, ¹Dept. of Rheumatology, Hospital of Southern Norway Trust, Kristiansand, Norway, ²Martina Hansens Hospital, Bærum, Norway, ³Dept. of Rheumatology, Hospital of Southern Norway Trust, kristiansand, Norway
Background/Purpose: The Maastricht Ankylosing Spondylitis Enthesitis Score (MASES) is an enthesitis index developed and validated as an outcome measure in ankylosing spondylitis (AS), but is…
Abstract Number: 1473 • 2017 ACR/ARHP Annual Meeting
Golimumab Improves Work Productivity and Activity Impairment in Patients with Rheumatoid Arthritis (RA), Ankylosing Spondylitis (AS) and Psoriatic Arthritis (PsA): Interim Results from a Non-Interventional Trial in Germany
Klaus Krüger¹, Sven Remstedt², Astrid Thiele³ and Ines Klaudius⁴, ¹Praxiszentrum St. Bonifatius München, München, Germany, ²Rheuma Praxis Berlin, Berlin, Germany, ³Krankenhaus St. Josef Wuppertal, Wuppertal, Germany, ⁴MSD Sharp & Dohme GmbH, Haar, Germany
Background/Purpose: In Germany no prospective data are available for Golimumab (GLM) in patients with RA, AS and PsAregarding outcomes evaluating work productivity and activity in…
Abstract Number: 1546 • 2017 ACR/ARHP Annual Meeting
Comparative Effectiveness of Secukinumab and Golimumab in Ankylosing Spondylitis: Assessed By Matching-Adjusted Indirect Comparison Using Pivotal Phase 3 Clinical Trial Data
Walter P. Maksymowych¹, Ernest Choy², Yusuf Yazici³, Jessica A. Walsh⁴, Howard Thom⁵, Chrysostomos Kalyvas⁶, Todd Fox⁷, Kunal Gandhi⁸ and Steffen Jugl⁷, ¹Radiology & Diagnostic Imaging, University of Alberta, Edmonton, AB, Canada, ²Section of Rheumatology, Cardiff University, Cardiff, Great Britain, ³School of Medicine, New York University School of Medicine, New York City, NY, ⁴Division of Rheumatology, University of Utah, Salt Lake City, UT, ⁵School of Social and Community Medicine, University of Bristol, Bristol, United Kingdom, ⁶Real World Strategy and Analytics, MAPI Group, Houten, Netherlands, ⁷Novartis Pharma AG, Basel, Switzerland, ⁸Novartis Pharmaceuticals Corporation, East Hanover, NJ
Background/Purpose: No data are available from head-to-head randomized controlled trials (RCTs) between secukinumab 150mg (SEC; an anti-IL-17A) and golimumab 50mg (GOL; a TNF inhibitor [TNFi])…
Abstract Number: 2506 • 2017 ACR/ARHP Annual Meeting
In Ankylosing Spondylitis/Axial Spondyloarthritis Smoking Is Associated with a Dose Related Elevation in CRP, Worse Disease Activity and Worse Quality of Life over One Year
Simon Stebbings¹, Mary Wallace², Andrew A. Harrison³, Nicola Dalbeth⁴, Douglas White⁵, Lisa K. Stamp⁶, Daniel Ching⁷ and John Highton⁸, ¹Dunedin Hospital, Department of Rheumatology, Dunedin, New Zealand, ²Surgical Sciences, University of Otago, Dunedin, New Zealand, ³Department of Medicine, University of Otago Wellington, Wellington, New Zealand, ⁴University of Auckland, Auckland, New Zealand, ⁵Department of Rheumatology, Waikato Clinical School, Hamilton, New Zealand, ⁶University of Otago, Christchurch, New Zealand, ⁷Timaru Medical Specialists Ltd, Timaru, New Zealand, ⁸Dept of Medicine, Univ of Otago Med Sch, Dunedin, New Zealand
Background/Purpose: Analysis of data from several cohort studies of patients with ankylosing spondylitis (AS) /axial spondyloarthritis (AxSpA) have confirmed earlier suggestions that current smokers have…
Abstract Number: 1512 • 2017 ACR/ARHP Annual Meeting
Is Sacroiliac Imaging the All-Decisive Factor in the Diagnosis of Early Axial Spondyloarthritis? Data from the Spondyloarthritis Caught Early (SPACE) Cohort
Zineb Ez-Zaitouni¹, Robert B.M. Landewé², Miranda van Lunteren¹, Pauline Bakker¹, Karen M Fagerli³, Roberta Ramonda⁴, Lennart TH Jacobsson⁵, Désirée van der Heijde⁶ and Floris van Gaalen⁷, ¹Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Amsterdam Rheumatology & Immunology Center, Amsterdam, Netherlands, ³Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁴Rheumatology Unit, University of Padova, Padova, Italy, ⁵Department of Rheumatology and Inflammation Research, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden, ⁶Leiden University Medical Center, Leiden, Netherlands, ⁷Rheumatology, Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: Imaging of the sacroiliac joints plays a pivotal role in the recognition of axSpA. However, interpretation of imaging is challenging and has led to…
Abstract Number: 1547 • 2017 ACR/ARHP Annual Meeting
Dose Tapering of TNFi in Patients with Axial Spondyloarthritis: An Observational Cohort Study from Nationwide Korean College of Rheumatology Biologic Registry (KOBIO)
Jun Won Park¹, Jin Kyun Park¹, Kichul Shin², Yong-Beom Park³, Eun Bong Lee¹, Yeong Wook Song⁴ and Eun Young Lee¹, ¹Division of Rheumatology, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea, Republic of (South), ²Kyungnam villa #102, Division of Rheumatology, Department of Internal Medicine, SMG-SNU Boramae Medical Center, Seoul, Korea, Republic of (South), ³Yonsei University Severance Hospital, Seoul, Korea, Republic of (South), ⁴Division of Rheumatology, Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea, Republic of (South)
Background/Purpose: To compare the clinical efficacy of dose-tapering strategy of tumor-necrosis factor inhibitor (TNFi) with that of standard-dose TNFi treatment in patients with spondyloarthritis (SpA)…
Abstract Number: 2511 • 2017 ACR/ARHP Annual Meeting
Irritable Bowel Syndrome and Its Impact on Patient-Reported Outcomes in Axial Spondyloarthritis: Is It an Overlooked Comorbidity?
Tor Olofsson¹, Elisabeth Mogard¹, Jan Marsal², Mats Geijer³, Lars Erik Kristensen⁴, Elisabet Lindqvist¹ and Johan K Wallman⁵, ¹Department of Clinical Sciences Lund, Rheumatology, Lund University, Lund, Sweden, ²Department of Clinical Sciences Lund, Gastroenterology, Lund University, Lund, Sweden, ³Department of Radiology, Faculty of Medicine and Health, Örebro University, Örebro, Sweden, ⁴Department of Rheumatology, Copenhagen University Hospital, Frederiksberg and Bispebjerg, The Parker Institute, Copenhagen, Denmark, ⁵Department of Clincial Sciences Lund, Rheumatology, Lund University, Lund, Sweden
Background/Purpose: While inflammatory bowel disease (IBD) is a well-known comorbidity in axial spondyloarthritis (SpA), little is known about functional bowel problems, such as irritable bowel…
Abstract Number: 1515 • 2017 ACR/ARHP Annual Meeting
Improvements in Enthesitis Scores with Certolizumab Pegol Treatment in Males and Females with Active Axial Spondyloarthritis Are Maintained to Week 204
Maxime Dougados¹, Philip J Mease², Joachim Sieper³, Peter C. Taylor⁴, Natasha de Peyrecave⁵, Tommi Nurminen⁶ and Jürgen Braun⁷, ¹Rheumatology Department, Paris-Descartes University and Cochin Hospital, Paris, France, ²Swedish Medical Center and University of Washington, Seattle, WA, ³Charité University Hospital, Berlin, Germany, ⁴Nuffield Dept. of Orthopaedics, Rheumatology and Musculoskeletal, Sciences, Kennedy Institute of Rheumatology, University of Oxford,, Oxford, United Kingdom, ⁵UCB Pharma, Slough, United Kingdom, ⁶UCB Pharma, Monheim, Germany, ⁷Rheumazentrum Ruhrgebiet, Herne, Germany
Background/Purpose: Axial spondyloarthritis (axSpA), characterized by spinal inflammation, is also associated with extra-spinal manifestations including inflammation of the entheses (enthesitis). Enthesitis is equally prevalent throughout…
Abstract Number: 1548 • 2017 ACR/ARHP Annual Meeting
Opioid Use in Patients with Ankylosing Spondylitis
Victor S. Sloan¹, Anna Sheahan¹, Jeffrey Stark² and Robert Y. Suruki¹, ¹UCB Pharma, Raleigh, NC, ²UCB Pharma, Smyrna, GA
Background/Purpose: The use or misuse of opioids has become a major public health issue in the USA. It is estimated that the economic burden of…
Abstract Number: 2513 • 2017 ACR/ARHP Annual Meeting
The Effect of Alcohol on Disease Activity in Axial Spondyloarthritis
Sizheng Zhao^1,2, Daniel Thong³, Stephen Duffield¹, David Hughes³ and Nicola Goodson^1,2, ¹Musculoskeletal Biology 1 Department, University of Liverpool, Liverpool, United Kingdom, ²Aintree University Hospital, Liverpool, United Kingdom, ³University of Liverpool, Liverpool, United Kingdom
Background/Purpose: There has been much interest in smoking as a modifiable risk factor for increased disease severity in rheumatic diseases. However, the effects of alcohol…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].